Preclinical jockeying on the translational track of adenosine A2A receptors

Experimental Neurology

Volumn 228, Issue 2, 2011, Pages 160-164

  Barkhoudarian, Melita T ^a   Schwarzschild, Michael A ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE A2A RECEPTOR; ADENOSINE A2A RECEPTOR AGONIST; BIIIB 014; CAFFEINE; DOPAMINE 1 RECEPTOR; GLUTAMIC ACID; ISTRADEFYLLINE; KW 6356; LEVODOPA; LU AA 27070; PLACEBO; PRELADENANT; ST 1535; SYN 115; THEOPHYLLINE; UNCLASSIFIED DRUG; VIPADENANT;

DISEASE MODEL; DISEASE SEVERITY; DRUG EFFICACY; DRUG INDICATION; DRUG SELECTIVITY; DYSKINESIA; EXTRAPYRAMIDAL SYNDROME; HAPLORHINI; HUMAN; LOW DRUG DOSE; NONHUMAN; NOTE; PARKINSON DISEASE; PRIORITY JOURNAL; RODENT;

ADENOSINE A2 RECEPTOR ANTAGONISTS; ANIMALS; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; DRUG DELIVERY SYSTEMS; DRUG EVALUATION, PRECLINICAL; HUMANS; PARKINSONIAN DISORDERS; RECEPTOR, ADENOSINE A2A; TRANSLATIONAL RESEARCH;

EID: 79952708899     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2010.12.022     Document Type: Note

References (54)

1. Arendash G.W., Cao C. Caffeine and coffee as therapeutics against Alzheimer's disease. J. Alzheimers Dis. 2010, 20(Suppl. 1):S117-S126.
2. Ascherio A., Zhang S.M., Hernán M.A., Kawachi I., Colditz G.A., Speizer F.E., Willett W.C. Prospective study of caffeine consumption and risk of Parkinson's disease in men and women. Ann. Neurol. 2001, 50(1):56-63.
3. 2A receptor antagonist treatment of Parkinson's disease. Neurology 2003, 61(3):293-296.
4. 2A adenosine receptors. Neuroscience 2010, 166(2):590-603.
5. 2A antagonist prevents dopamine agonist-induced motor complications in animal models of Parkinson's disease. Exp. Neurol. 2003, 184(1):285-294.
6. 2A antagonist SYN115 in Parkinson Disease. AAN Poster Discussion Session IV: Movement Disorders: Parkinson's Disease 2010, abstract.
7. 2a antagonist SYN115 in Parkinson Disease. J. Neurosci. 2010, 30(48):16284-16292.
8. 2A brain receptor occupancy of vipadenant (BIIB014) at steady-state levels in healthy male volunteers. Clin. Neuropharmacol. 2010, 33:55-60.
9. 2A receptor blockade prevents synaptotoxicity and memory dysfunction caused by beta-amyloid peptides via p38 mitogen-activated protein kinase pathway. J. Neurosci. 2009, 29(47):14741-14751.
10. 2A receptor heteromers. J. Neurosci. 2006, 26(7):2080-2087.
11. D'Agostino R.B. The delayed-start study design. N. Engl. J. Med. 2009, 361(13):1304-1306.
12. 2A receptor in mouse brain using the selective antagonist [3H]SCH 58261. Eur. J. Neurosci. 2001, 14:1567-1570.
13. 2A receptors and depression. Neurology 2003, 61(11 Suppl. 6):S82-S87.
14. Factor S., Mark M.H., Watts R., Struck L., Mori A., Ballerini R., Sussman N.M. A long-term study of istradefylline in subjects with fluctuating Parkinson's disease. Parkinsonism Relat. Disord. 2010, 16(6):423-426. Istradefylline 6002-US-007 Study Group.
15. Ferré S. Adenosine-dopamine interactions in the ventral striatum: implications for the treatment of schizophrenia. Psychopharmacology 1997, 133:107-120.
16. Ferré S., Fredholm B.B., Morelli M., Popoli P., Fuxe K. Adenosine-dopamine receptor-receptor interactions as an integrative mechanism in the basal ganglia. Trends Neurosci. 1997, 20(10):482-487.
17. 2A receptors in ventral striatum, hypothalamus and nociceptive circuitry implications for drug addiction, sleep and pain. Prog. Neurobiol. 2007, 83(5):332-347.
18. 2A adenosine receptors. J. Neurosci. 2002, 22(3):1054-1062.
19. Fredholm B.B., Bättig K., Holmén J., Nehlig A., Zvartau E.E. Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. Pharmacol. Rev. 1999, 51(1):83-133.
20. 2A receptor antagonist in MPTP-treated monkeys. Neurology 1999, 52(8):1673-1677.
21. 2A receptor antagonist istradefylline in advanced PD. Neurology 2003, 61(3):297-303. Istradefylline US-001 Study Group.
22. Hauser R.A., Shulman L.M., Trugman J.M., Roberts J.W., Mori A., Ballerini R., Sussman N.M. Study of istradefylline in patients with Parkinson's disease on L-Dopa with motor fluctuations. Mov. Disord. 2008, 23:2177-2185.
23. 2A antagonist, as an adjunct to Levodopa for the treatment of Parkinson's disease. Movement Disorder Society Meeting: Tu-185 2009, Abstract.
24. Hodgson R.A., Bertorelli R., Varty G.B., Lachowicz J.E., Forlani A., Fredduzzi S., Cohen-Williams M.E., Higgins G.A., Impagnatiello F., Nicolussi E., Parra L.E., Foster C., Zhai Y., Neustadt B.R., Stamford A.W., Parker E.M., Reggiani A., Hunter J.C. Characterization of the potent and highly selective A2A receptor antagonists preladenant and SCH 412348 [7-[2-[4-2, 4-difluorophenyl]-1-piperazinyl]ethyl]-2-(2-furanyl)-7H-pyrazol o[4, 3-e][1, 2, 4]triazolo[1, 5-c]pyrimidin-5-amine] in rodent models of movement disorders and depression. J. Pharmacol. Exp. Ther. 2009, 330(1):294-303.
25. 2A receptor antagonist, is active in primate models of movement disorders. Exp. Neurol. 2010, 225(2):384-390.
26. 2A receptor antagonist preladenant on dyskinesia in moderate to severe Parkinson's disease: post-hoc analysis of dose-finding study. Movement Disorder Society Meeting: Tu-187 2009, Abstract.
27. 2A antagonist: a novel antiparkinsonian agent that does not provoke dyskinesia in parkinsonian monkeys. Ann. Neurol. 1998, 43(4):507-513.
28. 2A antagonist KW-6002 with L-Dopa or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys. Exp. Neurol. 2000, 162(2):321-327.
29. 2A receptors in the motor effects of caffeine after its acute and chronic administration. Neuropsychopharmacology 2003, 28(7):1281-1291.
30. 1 antagonists on forepaw stepping in the unilateral 6-OHDA-lesioned rat. Psychopharmacology (Berl.) 2009, 201(4):529-539.
31. Kitagawa M., Houzen H., Tashiro K. Effects of caffeine on the freezing of gait in Parkinson's disease. Mov. Disord. 2007, 22(5):710-712.
32. Kyowa Hakko Kogyo Co., Ltd., 2008. Kyowa Hakko receives not approvable letter from FDA for istradefylline (KW-6002). Kyowa Kirin Press Release. [Internet, cited Nov 22 2010]. http://www.kyowa-kirin.co.jp/english/news/kyowa/er080228_01.html.
33. 2A receptor antagonist istradefylline (KW-6002) reduces "off" time in Parkinson's disease: a double-blind, randomized, multicenter clinical trial (6002-US-005). Ann. Neurol. 2008, 63:295-302.
34. Lundbeck A/S, 2007. Novel agent for treatment of Parkinson's disease in clinical development. Lundbeck Press Release. [Internet, cited Nov 22 2010]. http://www.lundbeck.com/investor/releases/ReleaseDetails/Release_1168032_EN.asp.
35. Lundbeck A/S, 2010. Lundbeck enters into license agreement with Kyowa Hakko Kirin for A2A antagonists for Parkinson's and other indications. Lundbeck Press Release. [Internet, cited Nov 22 2010]. http://es.lundbeck.com/investor/releases/ReleaseDetails/Release_1449056_EN.asp.
36. McGill University Health Center, 2009. Caffeine for Excessive Daytime Somnolence in Parkinson's Disease. In ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [cited Dec 13, 2010]. Available from: http://clinicaltrials.gov/ct2/show/NCT00459420.
37. McGill University Health Center, 2010. Caffeine for Motor Manifestations of Parkinson's Disease. In ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [cited Dec 13, 2010]. Available from: http://clinicaltrials.gov/ct2/show/NCT01190735.
38. Mizuno Y., Hasegawa K., Kondo T., Kuno S., Yamamoto M. Clinical efficacy of istradefylline (KW-6002) in Parkinson's disease: a randomized, controlled study. Mov. Disord. 2010, 25(10):1437-1443. Japanese Istradefylline Study Group.
39. Morelli M., Carta A.R., Kachroo A., Schwarzschild M.A. Pathophysiological roles for purines: adenosine, caffeine and urate. Prog. Brain Res. 2010, 183:183-208.
40. 2A receptors in rat and primate brain using [11C]SCH442416. Eur. J. Nucl. Med. Mol. Imaging 2005, 32:405-413.
41. 2A receptors: a new strategy for basal ganglia disorders. Recent Pat. CNS Drug Discov. 2007, 2(1):1-21.
42. 2A receptor antagonists: arylpiperazine derivatives of pyrazolo[4, 3-e]-1, 2, 4-triazolo[1, 5-c]pyrimidines. Bioorg. Med. Chem. Lett. 2007, 17(5):1376-1380.
43. 2A receptor antagonist BIIB014 is effective in improving ON-time in Parkinson's disease (PD) patients with motor fluctuations. Mov. Disord. 2010, 25(2):S305. (Abstract).
44. 2A receptor antagonists for Parkinson's disease. Expert Opin. Investig. Drugs 2009, 18(11):1619-1631.
45. 2A receptor antagonist SCH 58261 do not develop tolerance after repeated treatments in 6-hydroxydopamine-lesioned rats. Synapse 2001, 39(3):233-238.
46. Pires V.A., Pamplona F.A., Pandolfo P., Fernandes D., Prediger R.D., Takahashi R.N. Adenosine receptor antagonists improve short-term object-recognition ability of spontaneously hypertensive rats: a rodent model of attention-deficit hyperactivity disorder. Behav. Pharmacol. 2009, 20(2):134-145.
47. Schering-Plough, 2010. A placebo- and active-controlled study of preladenant in early Parkinson's disease (Study P05664AM2). In ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [cited Nov 22 2010]. Available from: http://clinicaltrials.gov/ct2/show/NCT01155479.
48. Simon D.K., Swearingen C.J., Hauser R.A., Trugman J.M., Aminoff M.J., Singer C., Truong D., Tilley B.C. NET-D Investigators. Caffeine and progression of Parkinson disease. Clin. Neuropharmacol. 2008, 31(4):189-196.
49. Stacy M., Silver D., Mendis T., Sutton J., Mori A., Chaikin P., Sussman N.M. A 12-week, placebo-controlled study (6002-US-006) of istradefylline in Parkinson disease. Neurology 2008, 70:2233-2240.
50. Takahashi R.N., Pamplona F.A., Prediger R.D. Adenosine receptor antagonists for cognitive dysfunction: a review of animal studies. Front. Biosci. 2008, 13:2614-2632.
51. Vernalis Co. Ltd., 2010. Vernalis announces A2A receptor antagonist programme for Parkinson's disease continues with next generation compound. Vernalis Press Release. [Internet, cited Nov 22 2010] 2A. http://www.vernalis.com/media-centre/latest-releases/584-vernalis-announces-a2A-receptor-antagonist-programme-for-parkinsons-disease-continues-with-next-generation-compound.
52. 2A receptor modulation. Neurology 2003, 61(11 Suppl. 6):S88-S93.
53. Xiao D., Bastia E., Xu Y.H., Benn C.L., Cha J.H., Peterson T.S., Chen J.F., Schwarzschild M.A. Forebrain adenosine A2A receptors contribute to l-3, 4-dihydroxyphenylalanine-induced dyskinesia in hemiparkinsonian mice. J. Neurosci. 2006, 26(52):13548-13555.
54. 2A Receptors Reduces l-3, 4-Dihydroxyphenylalanine-Induced Dyskinesia in a Model of Parkinson's Disease. Brain Res. 2010, 1367:310-318.